Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Cerenome, Inc. has secured up to $20 million in a financing facility with 3i Fund to support the commercial scale-up of its CNSide platform. The initial tranche of funding was received at closing with future tranches tied to milestones.
Cerenome, Inc. announced a senior secured financing agreement with 3i Fund for up to $20 million with royalty-based repayments. The initial funding was provided at closing, with future tranches linked to achieving certain milestones. This financing will aid in the scale-up of the Company’s CNSide cerebrospinal fluid assay platform
Company Information
Company
Cerenome
Location
Houston, Texas, United States
About
Cerenome is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide Diagnostics platform supports the detection, molecular characterization, and monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ, is designed to evaluate treatments for various CNS tumors. Cerenome is committed to improving patient care and creating long-term shareholder value.
Don't miss Cerenome's next move
Get an email the moment Cerenome raises, hires an exec, or expands, usually minutes after it happens.
HoustonBiotechnologyHealth CareTherapeuticsHealth Diagnostics